The benchmark for the efficacy of India's first coronavirus vaccine candidate COVAXIN is 60% and the efficacy results should be available by early April-May 2021, said Sai D Prasad, President-Quality Operations, Bharat Biotech. "WHO, US FDA and even India's CDSCO approve a respiratory vaccine if it achieves 50% efficacy; for COVAXIN, we aim to achieve at least 60%," Prasad added.